Goldman Sachs Group published a research report that according to SOTP, Kangze raised its target price from HK $16.86 to HK $18.88 and its rating from "neutral" to "buy", mainly because Goldman Sachs Group believes that the VBP uncertainty of the three core products (Deanxit, Plendil and Ursofalk) is decreasing, and the company is entering a new product cycle, especially the emerging dermatology products. It will boost revenue and profits in 2025 and beyond, accelerating back to 15% and 20%. The bank kept its profit forecast for 2023-25 unchanged.
大行评级｜高盛：上调康哲药业目标价至18.88港元 评级上调至“买入”
Bank Ratings | Goldman Sachs: Raising Kangzhe Pharmaceutical's target price to HK$18.88 and raising the rating to “buy”
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.